Revance Therapeutics Inc (NAS:RVNC)
$ 3.04 -0.02 (-0.65%) Market Cap: 317.35 Mil Enterprise Value: 618.80 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Revance Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 10:20PM GMT
Release Date Price: $10.8 (+1.22%)
Unidentified Analyst

We're happy to have Revance here with us. We have the CEO, Dan Browne, with us (inaudible). So he's going to (inaudible).

L. Daniel Browne
Revance Therapeutics, Inc. - Co-Founder, President, CEO & Director

Great. [Jason], thank you. Good afternoon, everyone, and thank you for joining us for a short conversation on Revance. This is an exciting time for the company as we look at putting ourselves in position to file our -- for our first approval here in the next several months and looking forward to launching the product next year.

On Slide 2, I'll be making some forward-looking statements. So I would ask each of you to look at this at your earliest opportunity.

Since we're working from the hard copy today, I just wanted to sort of highlight on Slide 3, the investments that we see looking at opportunities to create meaningful value in 3 distinct pillars of our business. First is the use of these very potent neuromodulators in aesthetics; further opportunities to create value on a therapeutic in a number of both neurologic and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot